top of page
Supported projects
BioSyngen
Specializing in the development of innovative cell therapies - chimeric antigen receptor T cells (CAR-T), T cell receptor T cells (TCR-T) and tumor-infiltrating lymphocytes (TIL) - for the treatment of cancer.
PSCC's entrance
March 2025
Localization
SG - Singapore
Modality
Cell & Gene therapy
Development status
Biotech - Phase 2
Award(s)
bottom of page